Lucid Diagnostics (LUCD) AI Stock Analysis

• Market Cap: $113.60M
• Dividend Yield: N/A
• Average Volume (3M): 1.47M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.14
• Revenue Growth: 39.89%
• EPS Growth: 5.87%
• Country: US
• Employees: 72
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Devices
• EPS (TTM): -0.16
• Shares Outstanding: 108,194,610
• 10 Day Avg. Volume: 2,049,310
• 30 Day Avg. Volume: 1,466,896
• PEG Ratio: -0.33
• Price to Book (P/B): -81.94
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -184.22
• Enterprise Value/Market Cap: 3.83
• Enterprise Value/Revenue: 26.34
• Enterprise Value/Gross Profit: -154.15
• Enterprise Value/Ebitda: -2.25
• 1Y Price Target: $3.79
• Price Target Upside: 260.95% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 41 Neutral
• Price Target: $1.00 ▼(-4.76%Downside)

Lucid Diagnostics faces severe financial challenges, with negative margins and cash flow issues weighing heavily on its valuation. Despite positive corporate events, the bearish technical indicators and poor valuation metrics contribute to a low overall stock score.

Positive Factors

Medicare Coverage

Medicare coverage appears imminent, which could lead to a significant increase in test volume and revenue from Medicare patients and benefit commercial/private payer adoption.

Potential Acquisition

EsoGuard's huge first mover advantage and better test makes Lucid a very attractive potential acquisition candidate.

Strategic Partnerships

LUCD partnered with a major health system to expand access to its EsoGuard testing program, which is expected to broaden adoption and drive topline growth.

Negative Factors

Commercialization Challenges

Lucid’s devices still have long commercialization and growth challenges ahead.

Financial Performance

Lucid reported 1Q25 revenue that was below analyst estimates and FactSet consensus.

Revenue Miss

LUCD missed consensus revenue due partly to temporary payment delays at United Healthcare.

Lucid Diagnostics Business Overview & Revenue Model

Company Description

Lucid Diagnostics (LUCD) is a medical diagnostics company focused on the development and commercialization of diagnostic tests for the early detection of esophageal precancer and cancer. The company's core product is the EsoGuard Esophageal DNA Test, which is designed to detect genetic abnormalities indicative of esophageal cancer and precancerous conditions, such as Barrett's Esophagus, using a non-invasive method. Lucid Diagnostics operates in the healthcare sector, specifically within the molecular diagnostics and gastrointestinal health fields.

How the Company Makes Money

Lucid Diagnostics generates revenue primarily through the sale and distribution of its EsoGuard Esophageal DNA Test. The company earns money by partnering with healthcare providers, including hospitals, clinics, and gastroenterologists, who administer the test to patients. These partnerships are crucial as they extend the reach of EsoGuard to patients who are at risk of esophageal cancer or precancerous conditions. Revenue is primarily driven by the volume of tests conducted and processed, as well as through reimbursement agreements with insurance companies and healthcare payers. Additionally, Lucid Diagnostics may engage in research collaborations and licensing agreements to further expand its diagnostic offerings and market presence.

Lucid Diagnostics Financial Statement Overview

Summary

Lucid Diagnostics is experiencing rapid revenue growth but is struggling with profitability, cash flow, and leverage. The company faces high operating losses and negative cash flows, indicating significant financial instability. While there are some improvements in equity, substantial risks remain due to reliance on debt and negative margins.

Income Statement

Lucid Diagnostics has shown significant revenue growth from 2023 to 2024 with a revenue growth rate of 178883%. However, the company is still experiencing negative gross profit and net income, leading to negative margins. The net profit margin and EBIT margin are severely negative, indicating substantial losses relative to revenue. The financials reflect a challenging profitability position.

Balance Sheet

The company's debt-to-equity ratio has seen improvement due to rising stockholders' equity but remains concerning. The equity ratio is low, indicating heavy reliance on liabilities. The company's assets are largely financed through debt and liabilities, posing a risk amidst negative equity in previous years. However, the current positive equity marks a potential recovery trajectory.

Cash Flow

Lucid Diagnostics has a negative free cash flow, indicating significant cash outflow. The operating cash flow to net income ratio is negative, reflecting operational challenges. The company heavily relies on financing activities to manage cash flow, which is unsustainable in the long term. Improvement in cash generation from operations is crucial.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.17M	4.35M	2.43M	377.00K	500.00K	0.00
Gross Profit	-2.82M	-3.92M	-6.05M	-3.24M	-85.00K	0.00
EBITDA	-60.91M	-44.34M	-49.75M	-54.23M	-27.41M	482.00
Net Income	-61.83M	-45.53M	-52.67M	-56.17M	-28.08M	-8.28M
Balance Sheet
Total Assets	32.80B	30.71M	27.27M	32.51M	59.00M	2.19M
Cash, Cash Equivalents and Short-Term Investments	25.24B	22.36B	18.90M	22.47M	53.66M	111.25K
Total Debt	35.27B	21.25M	15.26M	2.00M	0.00	0.00
Total Liabilities	38.17B	25.32M	29.58M	9.46M	4.26M	15.71M
Stockholders Equity	-5.38B	5.39B	-2.31M	23.05M	54.74M	-13.52M
Cash Flow
Free Cash Flow	-12.50B	-44.79M	-33.04M	-30.59M	-18.53M	-5.63M
Operating Cash Flow	-12.50B	-44.14M	-32.82M	-29.68M	-17.67M	-5.63M
Investing Cash Flow	-480.22M	-646.00K	-221.00K	-4.11M	-862.00K	0.00
Financing Cash Flow	15.47B	48.25M	29.46M	2.61M	72.08M	5.58M

Lucid Diagnostics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LUCD, the sentiment is Negative. The current price of 1.05 is below the 20-day moving average (MA) of 1.22, below the 50-day MA of 1.27, and below the 200-day MA of 1.10, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 31.36 is Neutral, neither overbought nor oversold. The STOCH value of 13.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LUCD.

Lucid Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NKTR	54 Neutral	$316.75M	―	-189.46%	―	-3.24%	31.00%
Sector *	51 Neutral	$7.50B	0.32	-61.87%	2.27%	17.10%	1.59%
LUCD	41 Neutral	$113.60M	―	-1897.35%	―	39.89%	5.87%
LXEO	38 Underperform	$145.40M	―	-80.65%	―	―	-24.18%
BIOA	33 Underperform	$148.06M	―	-30.20%	―	―	―

Lucid Diagnostics Corporate Events

Lucid Diagnostics Holds Annual Stockholders Meeting

On June 18, 2025, Lucid Diagnostics Inc. held its annual meeting of stockholders, where approximately 70.9% of the shares were represented. During the meeting, the stockholders elected management’s nominees for director and approved other key proposals, including the issuance of common stock under the 2024 Convertible Notes and the ratification of CBIZ CPAs P.C. as the company’s independent accounting firm for 2025. These approvals are expected to support Lucid Diagnostics’ strategic initiatives and strengthen its financial and operational framework.

The most recent analyst rating on (LUCD) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.

Lucid Diagnostics Enters $25M Sales Agreement

On May 30, 2025, Lucid Diagnostics Inc. entered into a Sales Agreement with Maxim Group LLC to offer and sell up to $25,000,000 of its common stock through an at-the-market offering. The proceeds from this offering are intended for working capital and general corporate purposes, potentially impacting the company’s operational capabilities and market positioning.

The most recent analyst rating on (LUCD) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.

Lucid Diagnostics Reports Q1 2025 Financial Results

On May 14, 2025, Lucid Diagnostics reported its financial results for the first quarter of 2025, processing 3,034 EsoGuard tests and generating $0.8 million in revenue. The company secured additional capital, extending its financial runway beyond key reimbursement milestones, and launched initiatives to expand its market reach, including a partnership with a major health system and a new campaign for its EsoCheck device. Despite a net loss of $36 million, Lucid strengthened its balance sheet through stock offerings and continued to gain traction in various sales channels, positioning itself for future growth.

The most recent analyst rating on (LUCD) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.

Lucid Diagnostics Closes $16.1 Million Public Offering

On April 11, 2025, Lucid Diagnostics Inc. announced the closing of its public offering of 14,375,000 shares of common stock at $1.20 per share, raising approximately $16.1 million in net proceeds. The funds will be used for working capital and general corporate purposes, with Canaccord Genuity LLC and Maxim Group LLC managing the offering. This move is expected to bolster Lucid’s financial position as it continues to focus on cancer prevention diagnostics.

Lucid Diagnostics Announces Public Stock Offering

On April 9, 2025, Lucid Diagnostics announced an underwritten public offering of its common stock, with Canaccord Genuity LLC as the sole bookrunner. The offering, priced at $1.20 per share, aims to raise approximately $15 million, with proceeds intended for working capital and general corporate purposes. The sale of 12,500,000 shares is expected to close around April 11, 2025, subject to customary closing conditions. The offering is made under an existing shelf registration statement, and the company has granted underwriters a 45-day option to purchase additional shares.